Preclinical Studies on Histone Deacetylase Inhibitors as Therapeutic Reagents for Endometrial and Ovarian Cancers

Future Oncology - United Kingdom
doi 10.2217/fon.11.124
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd

Related search

Activity of PXD101, a Histone Deacetylase Inhibitor, in Preclinical Ovarian Cancer Studies

Molecular Cancer Therapeutics
Cancer ResearchOncology
2006English

Histone Deacetylase Inhibitors as Therapeutic Agents for Cancer Therapy: Drug Metabolism and Pharmacokinetic Properties

2011English

Histone Deacetylase Inhibitors as Cancer Therapeutics

Annals of Translational Medicine
Medicine
2016English

Toward Isozyme-Selective Inhibitors of Histone Deacetylase as Therapeutic Agents for the Treatment of Cancer

Pharmaceutical patent analyst
MedicineDrug DiscoveryPharmaceutical Science
2012English

Inhibitors of Histone-Deacetylase

Journal of Applied Biomedicine
GeneticsMolecular BiologyPharmacologyBiochemistryBiological SciencesToxicologyMedicineAgriculturalNeurosciencePharmaceutics
2005English

Pharmacogenomics and Histone Deacetylase Inhibitors

Pharmacogenomics
Molecular MedicineGeneticsPharmacology
2016English

Development of Histone Deacetylase Inhibitors as Therapeutics for Neurological Disease

Future Neurology
Neurology
2009English

Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors

Journal of Biomedicine and Biotechnology
2011English

Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy